Literature DB >> 4050455

Comparison of the calcium-antagonistic effects of terodiline, nifedipine and verapamil.

C Larsson-Backström, E Arrhenius, K Sagge.   

Abstract

Studies were carried out on the Ca-antagonistic effects of terodiline and its enantiomers on the potassium-stimulated mesenteric and coronary arteries, on the spontaneous myogenic activity and norepinephrine- and acetylcholine-induced contractions of the protal vein and on electrically stimulated papillary muscle. The effects were compared with those of the Ca-antagonists, nifedipine and verapamil. Terodiline is relatively weak as a Ca-antagonist, having IC50-values between 5 X 10(-6) and 2 X 10(-5)M for all the tissues studied. Nifedipine is the most potent Ca-antagonist on vascular smooth muscle (IC50 3-6 X 10(-9) M), but is considerably less potent on the papillary muscle (IC50 10(-7)M). Verapamil is most potent on the papillary muscle (IC50 7 X 10(-8)M and the portal vein (IC50 6 X 10(-8)M, but is 10 times less potent on the mesenteric and coronary arteries (IC50 3-5 X 10(-7)M). Nifedipine is 1000 times and verapamil and (-)-terodiline 10 times more potent on the slow component of the K-induced contraction while (+/-)- and (+)-terodiline are almost as active on the fast as on the slow component of K-induced contractions on the mesenteric artery. Furthermore, (+/-)-and (+)-terodiline are 10 times more potent in antagonizing acetylcholine- and norepinephrine-induced contractions, whereas (-)-terodiline is equally potent and nifedipine and verapamil are 10 times more potent in blocking the myogenic activity of the portal vein. On the Ca2+-nifedipine and verapamil. However, nifedipine and verapamil, but not terodiline, in concentrations which blocked the maximal norepinephrine-induced response in non-depleted muscle, antagonized the contractions induced by norepinephrine together with Ca2+ in the Ca2+ depleted portal vein. These results show that terodiline blocks the uptake of Ca2+ and, in addition, blocks the utilization of some intracellular stores of Ca2+.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4050455     DOI: 10.1111/j.1600-0773.1985.tb00002.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  7 in total

1.  Block and modified gating of cardiac calcium channel currents by terodiline.

Authors:  T Ogura; S Jones; L M Shuba; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 3.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

4.  Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.

Authors:  Dharini van der Hoeven; Kwang-jin Cho; Xiaoping Ma; Sravanthi Chigurupati; Robert G Parton; John F Hancock
Journal:  Mol Cell Biol       Date:  2012-11-05       Impact factor: 4.272

5.  Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

Authors:  S H Thomas; P D Higham; K Hartigan-Go; F Kamali; P Wood; R W Campbell; G A Ford
Journal:  Br Heart J       Date:  1995-07

6.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

Review 7.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.